“Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies”, J of Skin, vol. 7, no. 6, p. s294, Nov. 2023, doi: 10.25251/skin.7.supp.294.